作者: Katherine E. Warren , Tina Y. Poussaint , Gilbert Vezina , Darren Hargrave , Roger J. Packer
DOI: 10.1002/PBC.24562
关键词:
摘要: Criteria for new drug approval include demonstration of efficacy. In neuro-oncology, this is determined radiographically utilizing tumor measurements on MRI scans. Limitations method have been identified where activity not reflected in decreased size. The RANO (Response Assessment Neuro-Oncology) working group was established to address limitations defining endpoints clinical trials adult neuro-oncology and develop standardized response criteria. RAPNO subsequently unique issues pediatric neuro-oncology. aim paper delineate criteria as a basis subsequent recommendations.